{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:41:36Z","timestamp":1789072896935,"version":"build-2803163510"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2025-03045_VR"],"award-info":[{"award-number":["2025-03045_VR"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["environment grant 2024-06502"],"award-info":[{"award-number":["environment grant 2024-06502"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017156","name":"Swedish e-Science Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN21\/1512"],"award-info":[{"award-number":["CAN21\/1512"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Prostate Cancer Society"},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["HEAP grant No. 874662"],"award-info":[{"award-number":["HEAP grant No. 874662"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>While the prostate-specific antigen (PSA) test is a widely used prostate cancer screening tool, its application remains controversial. Opportunistic PSA testing generates complex data in which testing intensities, PSA levels, and prostate cancer diagnosis are interdependent. Conventional analyses rarely model these processes jointly. The objective of this study was to develop a population-based joint model to analyse PSA dynamics, retesting patterns, and prostate cancer risk. We used the Stockholm Prostate Cancer Diagnostics Register to identify 506,761 men with at least one PSA test between 2003 and 2020. We fitted a joint model linking three components: a linear mixed-effects submodel for PSA over age, and two proportional hazards submodels for time to next PSA test and time to prostate cancer diagnosis. PSA increased nonlinearly with age, with substantial between-person heterogeneity and increasing unexplained variation with increasing age. Estimates from models fitted to each time-to-event process separately were attenuated relative to the joint model: hazard ratios per doubling of PSA were 1.61 (95% CI: 1.59-1.62; P\u2009&lt;\u2009.001) versus 2.01 (95% CI: 1.99-2.02; P\u2009&lt;\u2009.001) for prostate cancer diagnosis, respectively, and 1.068 (95% CI: 1.066-1.070; P\u2009&lt;\u2009.001) versus 1.163 (95% CI: 1.161-1.165; P\u2009&lt;\u2009.001) for retesting, respectively. This pattern is consistent with informative observation bias: men with higher PSA values are tested more frequently, so that part of the association between PSA and the event is absorbed by the unmodelled observation mechanism when the processes are analysed separately. Jointly modelling PSA, testing intensity, and diagnosis through shared random effects accounts for this dependence. As a limitation, the study is primarily limited by its observational nature and a lack of data on non-cancer factors that can elevate PSA, such as urinary tract infections or lower urinary tract symptoms. In conclusion, jointly modelling PSA dynamics and testing behaviour corrects for the informative observation bias inherent in opportunistic testing. This approach yields more accurate population estimates compared to traditional isolated models. Our findings suggest that PSA dynamics may be clinically informative and that screening models should jointly incorporate testing history and PSA trajectories to improve precision.<\/jats:p>","DOI":"10.1371\/journal.pone.0343751","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:49:01Z","timestamp":1783705741000},"page":"e0343751","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Joint modelling of PSA dynamics and prostate cancer risks: A population-based study in men without prior prostate cancer"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2327-6156","authenticated-orcid":true,"given":"Birzhan","family":"Akynkozhayev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Christoffersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"pone.0343751.ref001","volume-title":"ECIS - European Cancer Information System. Incidence and Mortality 2020","author":"European Union","year":"2023"},{"key":"pone.0343751.ref002","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","author":"D Ilic","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"pone.0343751.ref003","doi-asserted-by":"crossref","first-page":"192","DOI":"10.7326\/0003-4819-149-3-200808050-00009","article-title":"Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force","volume":"149","author":"K Lin","year":"2008","journal-title":"Ann Intern Med"},{"issue":"7","key":"pone.0343751.ref004","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7326\/M17-2012","article-title":"Prostate Cancer Screening: Time to Question How to Optimize the Ratio of Benefits and Harms","volume":"167","author":"AJ Vickers","year":"2017","journal-title":"Ann Intern Med"},{"key":"pone.0343751.ref005","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European Study of Prostate Cancer Screening \u2014 23-Year Follow-Up","volume":"393","author":"MJ Roobol","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"pone.0343751.ref006","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial","volume":"331","author":"RM Martin","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"pone.0343751.ref007","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cncr.30474","article-title":"Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years","volume":"123","author":"PF Pinsky","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"pone.0343751.ref008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0090-4295(00)00637-3","article-title":"Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging","volume":"56","author":"WJ Catalona","year":"2000","journal-title":"Urology"},{"issue":"1","key":"pone.0343751.ref009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eeus.2006.10.003","article-title":"Age-Specific Reference Ranges for Prostate-Specific Antigen as a Marker for Prostate Cancer","volume":"5","author":"H-J Luboldt","year":"2007","journal-title":"EAU-EBU Update Series"},{"issue":"2","key":"pone.0343751.ref010","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.juro.2006.09.063","article-title":"Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening","volume":"177","author":"JW Moul","year":"2007","journal-title":"J Urol"},{"issue":"16","key":"pone.0343751.ref011","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.1992.03480160073037","article-title":"Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease","volume":"267","author":"HB Carter","year":"1992","journal-title":"JAMA"},{"issue":"17","key":"pone.0343751.ref012","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"WJ Catalona","year":"1991","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0343751.ref013","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.urology.2013.09.075","article-title":"A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer","volume":"83","author":"AJ Vickers","year":"2014","journal-title":"Urology"},{"issue":"4","key":"pone.0343751.ref014","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bjmsu.2011.08.006","article-title":"PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer","volume":"5","author":"AJ Vickers","year":"2012","journal-title":"Br J Med Surg Urol"},{"issue":"8","key":"pone.0343751.ref015","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1464-410X.2012.11651.x","article-title":"Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population","volume":"111","author":"LP Wallner","year":"2013","journal-title":"BJU Int"},{"key":"pone.0343751.ref016","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fonc.2018.00296","article-title":"Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort","volume":"8","author":"RJ Karnes","year":"2018","journal-title":"Front Oncol"},{"key":"pone.0343751.ref017","doi-asserted-by":"crossref","first-page":"102338","DOI":"10.1016\/j.canep.2023.102338","article-title":"Changes in prostate specific antigen (PSA) \u201cscreening\u201d patterns by geographic region and socio-economic status in Australia: Analysis of medicare data in 50-69 year old men","volume":"83","author":"A Kohar","year":"2023","journal-title":"Cancer Epidemiol"},{"key":"pone.0343751.ref018","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eururo.2012.10.001","article-title":"Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003\u20132011","volume":"63","author":"T Nordstr\u00f6m","year":"2013","journal-title":"Eur Urol"},{"issue":"9","key":"pone.0343751.ref019","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/cncr.22607","article-title":"Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey","volume":"109","author":"AB Mariotto","year":"2007","journal-title":"Cancer"},{"key":"pone.0343751.ref020","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083800","article-title":"Prostate specific antigen retesting intervals and trends in England: population based cohort study","volume":"391","author":"KK Collins","year":"2025","journal-title":"BMJ"},{"issue":"22","key":"pone.0343751.ref021","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1002\/sim.6972","article-title":"Joint modelling of longitudinal and multi-state processes: application to clinical progressions in prostate cancer","volume":"35","author":"L Ferrer","year":"2016","journal-title":"Stat Med"},{"issue":"1","key":"pone.0343751.ref022","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0962280212445839","article-title":"Joint latent class models for longitudinal and time-to-event data: a review","volume":"23","author":"C Proust-Lima","year":"2014","journal-title":"Stat Methods Med Res"},{"issue":"5","key":"pone.0343751.ref023","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1177\/09622802241239003","article-title":"Using joint models for longitudinal and time-to-event data to investigate the causal effect of salvage therapy after prostatectomy","volume":"33","author":"D Rizopoulos","year":"2024","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"pone.0343751.ref024","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyaf062","article-title":"Data Resource Profile: STHLM0, the Stockholm Prostate Cancer Diagnostics Register","volume":"54","author":"A Abbadi","year":"2025","journal-title":"Int J Epidemiol"},{"key":"pone.0343751.ref025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.euros.2026.03.015","article-title":"Trends and patterns in prostate cancer diagnostics during the era of MRI implementation \u2013 real-world evidence from a population-based study in the Stockholm region, Sweden 2010\u20132023","volume":"87","author":"J Chandra Engel","year":"2026","journal-title":"Eur Urol Open Sci"},{"key":"pone.0343751.ref026","doi-asserted-by":"crossref","DOI":"10.1198\/jcgs.2011.09118","article-title":"Gaussian variational approximate inference for generalized linear mixed models","volume":"21","author":"JT Ormerod","year":"2012","journal-title":"Journal of Computational and Graphical Statistics"},{"key":"pone.0343751.ref027","article-title":"Joint models with multiple markers and multiple time-to-event outcomes using variational approximations","author":"B Christoffersen","year":"2025","journal-title":"arXiv"},{"issue":"4","key":"pone.0343751.ref028","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/biostatistics\/kxq036","article-title":"Calibrating disease progression models using population data: a critical precursor to policy development in cancer control","volume":"11","author":"R Gulati","year":"2010","journal-title":"Biostatistics"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0343751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:49:07Z","timestamp":1783705747000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0343751"}},"subtitle":[],"editor":[{"given":"Stanis\u0142aw Jacek","family":"Wro\u0144ski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0343751","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}